{"ticker": {"uuid": "02f63602-b4a8-4c7c-9f61-de7535f8755d", "symbol": "REPL", "name": "Replimune Group Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Replimune stock gains after updated RP1 data and cash runway outlook", "summary": "Replimune Group Inc. (REPL) stock is reacting to updated clinical data for its oncolytic immunotherapy RP1 and a strengthened cash position. The company reported $357 million in cash and short-term investments as of March 31, 2024, which management expects will fund operations in", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/replimune-stock-gains-after-updated-rp1-data-and-cash-runway-outlook/69827956", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T20:40:09", "published_display": "21 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Replimune Group, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Replimune Group, Inc. (A2JQN1) stocks, offering investors diversified exposure to the company. The ETFs are sorted by their market value of Replimune holdings and include details such as issuer, management style, e", "url": "https://www.tradingview.com/symbols/LS-A2JQN1/etfs/", "source_name": "TradingView", "published_at": "2026-07-20T16:10:26", "published_display": "20 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Liquidity Mapping Around (REPL) Price Events", "summary": "This article analyzes Replimune Group Inc. (NASDAQ: REPL) stock, identifying weak near- and mid-term sentiment with a neutral long-term outlook. It highlights an exceptional risk-reward short setup and provides three AI-generated trading strategies tailored for different risk pro", "url": "https://news.stocktradersdaily.com/news_release/78/Liquidity_Mapping_Around_REPL_Price_Events_071526054201_1784151721.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T17:42:00", "published_display": "15 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 27, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)", "summary": "Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Replimune Group, Inc. (REPL) on behalf of long-term shareholders who held shares continuously since prior to November 22, 2024. The investigation stems from allegatio", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327933/0/en/johnson-fistel-pllp-investigates-claims-on-behalf-of-long-term-shareholders-of-replimune-group-inc-repl.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T15:11:07", "published_display": "15 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Replimune Group, Inc. \u2013 MUN:7R8", "summary": "This article provides the \"Price to earnings forward\" value for Replimune Group, Inc. (MUN:7R8). It indicates that the market is currently closed with no trades. The information is presented on a TradingView page, which also lists various data sources and company information.", "url": "https://www.tradingview.com/symbols/MUN-7R8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T10:12:09", "published_display": "14 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (NASDAQ: REPL) seeks approval to double authorized stock", "summary": "Replimune Group (NASDAQ: REPL) is seeking stockholder approval to amend its charter to double the authorized common stock from 150,000,000 to 300,000,000 shares. This proposal, requiring 75% approval, is part of three proposals to be voted on at the virtual 2026 annual meeting on", "url": "https://www.stocktitan.net/sec-filings/REPL/pre-14a-replimune-group-inc-preliminary-proxy-statement-16079e2475c5.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:42:46", "published_display": "13 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form PRE 14A REPLIMUNE GROUP For: 13 July By Investing.com", "summary": "Investing.com has published a Form PRE 14A for Replimune Group dated July 13. The article provides the filing details, indicates it's from Reuters, and includes the current stock performance for REPL. It also shows a snapshot of various market indices and commodities.", "url": "https://ca.investing.com/news/stock-market-news/form-pre-14a-replimune-group-for-13-july-93CH-4731984", "source_name": "Investing.com Canada", "published_at": "2026-07-13T21:31:10", "published_display": "13 Jul 2026 21:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (REPL) Q4 2026 earnings summary", "summary": "Replimune Group (REPL) reported its Q4 2026 earnings, highlighting the FDA's acceptance of the BLA resubmission for RP1 in advanced melanoma, with a goal date of August 2, 2026. The company experienced a net loss of $313.9 million for the year while its cash reserves decreased to", "url": "https://quartr.com/events/replimune-group-inc-repl-q4-2026_FeJwsKTa", "source_name": "Quartr", "published_at": "2026-07-13T20:42:46", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This NASDAQ page provides live quotes and charts for Replimune Group Inc. (REPL), showing its current stock price and basic performance data. It also includes sections for analyst ratings and earnings information, although specific data for these categories are marked as \"N/A\" or", "url": "https://timothysykes.com/quote/REPL/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:10:52", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock and its cancer immunotherapy pipeline", "summary": "Replimune Group Inc. (REPL) is a Nasdaq-listed biotech company specializing in oncolytic immunotherapies for cancer. Their strategy involves engineering viruses to selectively infect and kill cancer cells, while also stimulating an immune response to \"turn cold tumors hot.\" The c", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/replimune-group-stock-and-its-cancer-immunotherapy-pipeline/69724494", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T14:10:56", "published_display": "08 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune says FDA rejected its lead drug for skin cancer", "summary": "Replimune announced that the FDA has rejected its lead drug for skin cancer. The rejection impacts the company's primary therapeutic candidate and its development pipeline.", "url": "https://www.msn.com/en-us/news/other/replimune-says-fda-rejected-its-lead-drug-for-skin-cancer/ar-AA1J3LZ7?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-03T19:09:39", "published_display": "03 Jul 2026 19:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REPL Stock Lost 19% Of Its Value Today \u2013 Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?", "summary": "Replimune Group Inc. (REPL) saw its stock drop 19% after the FDA refused approval for its experimental melanoma drug, RP1. The FDA deemed the submitted data \"insufficient to conclude substantial evidence of effectiveness\" and had previously rejected the initial application in Jul", "url": "https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto", "source_name": "Stocktwits", "published_at": "2026-07-01T05:10:11", "published_display": "01 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bmo-capital-upgrades-replimune-outperform-103226217.html", "source_name": "MT Newswires", "published_at": "2026-06-30T10:32:26+00:00", "published_display": "30 Jun 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update", "summary": "Replimune has released its financial results for the fiscal fourth quarter and year ended March 31, 2026. The report includes key financial figures and a corporate update, offering insights into the company's performance and strategic initiatives for the past year and future outl", "url": "https://www.moomoo.com/hans/news/post/72189851/press-release-replimune-reports-fiscal-fourth-quarter-and-year-end?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T05:10:11", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune's Fiscal Q4 Net Loss Narrows", "summary": "Replimune (NASDAQ: REPL) reported a narrower net loss for its fiscal fourth quarter, coming in at $0.78 per share compared to $0.85 per share in the prior year. The company's total revenue for the quarter was $7.3 million, primarily driven by product sales. Replimune is an oncolo", "url": "https://www.moomoo.com/news/post/72191313/replimune-s-fiscal-q4-net-loss-narrows", "source_name": "Moomoo", "published_at": "2026-06-29T18:41:11", "published_display": "29 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-lifts-price-target-replimune-155544822.html", "source_name": "MT Newswires", "published_at": "2026-06-29T15:55:44+00:00", "published_display": "29 Jun 2026 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Inc reports results for the quarter ended March 31 - Earnings Summary", "summary": "Replimune Group Inc has released its earnings summary for the quarter ended March 31. The report contains financial results for the specified period. Further details are available through the provided source, Refinitiv.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N4310ZH:0-replimune-group-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-06-29T12:39:57", "published_display": "29 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA", "summary": "Replimune Group, Inc. (REPL) reported a widened net loss of $313.9 million for fiscal year 2026, compared to $247.3 million in the previous year, with operating expenses reaching $319.9 million. Despite the increased losses and a reduced cash position of $268.9 million (expected ", "url": "https://www.stocktitan.net/sec-filings/REPL/8-k-replimune-group-inc-reports-material-event-9445d6900162.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:39:57", "published_display": "29 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M \u2014 10-K Summary", "summary": "Replimune Group, Inc. reported a net loss of $(313.94)M for fiscal year 2026, an increase from the $(247.30)M net loss in fiscal 2025, with no reported product revenue. The company is actively investing in research and development for its lead programs RP1, RP2, and RP3, advancin", "url": "https://www.tradingview.com/news/tradingview:252b2617eacb4:0-replimune-group-fy-2026-revenue-0-net-loss-313-9-m-10-k-summary/", "source_name": "TradingView", "published_at": "2026-06-29T12:39:57", "published_display": "29 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune upgraded by Analyst with a new price target", "summary": "Replimune (REPL) has received a new analyst upgrade, which was promptly alerted to Quantisnow Plus members. The company's stock is being watched by Beagle, a market research tool that provides real-time alerts on news, SEC filings, and other market-moving events. Quantisnow is a ", "url": "https://www.quantisnow.com/insight/replimune-upgraded-by-analyst-with-a-new-price-target-6617005", "source_name": "Quantisnow", "published_at": "2026-06-29T12:10:44", "published_display": "29 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune\u2019s melanoma drug review moves toward Aug. 2 FDA decision", "summary": "Replimune reported its fiscal Q4 and full-year 2026 financial results, with a net loss of $313.9 million, and provided a corporate update. The FDA accepted the BLA resubmission for RP1 + nivolumab in advanced melanoma, setting an August 2, 2026 goal date and an advisory committee", "url": "https://www.stocktitan.net/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-uf2j34aykgsk.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:39:57", "published_display": "29 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update", "summary": "Replimune Group, Inc. has announced its financial results for the fiscal fourth quarter and year ended March 31, 2026, alongside a significant corporate update. The FDA has accepted the resubmission of their Biologics License Application (BLA) for RP1 in combination with nivoluma", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-results-and-provides-corporate-update/2374827", "source_name": "The Manila Times", "published_at": "2026-06-29T11:39:57", "published_display": "29 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class Action - Contact Levi & Korsinsky", "summary": "Levi & Korsinsky LLP has issued an investor alert for Replimune Group, Inc. (REPL) shareholders, reminding them about the approaching deadline to join a class action lawsuit. The lawsuit alleges that Replimune made false statements regarding its IGNYTE trial, which resulted in th", "url": "https://natlawreview.com/press-releases/investor-alert-deadline-approaching-join-replimune-group-inc-repl-class", "source_name": "The National Law Review", "published_at": "2026-06-28T15:10:46", "published_display": "28 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma", "summary": "Replimune Group, Inc. announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma. The FDA considers this a complete, class 1 response, with a decision expected by August 2, 2026, and ", "url": "https://www.manilatimes.net/2026/06/26/tmt-newswire/globenewswire/replimune-announces-fda-acceptance-of-rp1-biologics-license-application-resubmission-for-advanced-melanoma/2373657/amp", "source_name": "The Manila Times", "published_at": "2026-06-26T20:06:00", "published_display": "26 Jun 2026 20:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-upgrades-replimune-group-overweight-155618861.html", "source_name": "MT Newswires", "published_at": "2026-06-26T15:56:18+00:00", "published_display": "26 Jun 2026 15:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.", "summary": "Replimune Group Inc. has announced that the U.S. FDA has accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1, intended for advanced melanoma treatment. This marks a significant step in the marketing process for their oncolytic virus im", "url": "https://www.bitget.com/amp/news/detail/12560605479113", "source_name": "Bitget", "published_at": "2026-06-26T15:10:24", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Says FDA Accepts Melanoma Drug Resubmission, Sets Aug. 2 Target Action Date", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/replimune-says-fda-accepts-melanoma-123655329.html", "source_name": "MT Newswires", "published_at": "2026-06-26T12:36:55+00:00", "published_display": "26 Jun 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Replimune\u2019s resubmitted application for RP1", "summary": "The FDA has accepted Replimune Group, Inc.'s resubmitted Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, classifying it as a complete, class 1 response with a goal date of August 2, 2026. An advisory committee meeting is scheduled for la", "url": "https://www.investing.com/news/company-news/fda-accepts-replimunes-resubmitted-application-for-rp1-93CH-4762677", "source_name": "Investing.com", "published_at": "2026-06-26T13:09:20", "published_display": "26 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Replimune Group, Inc. \u2013 NASDAQ:REPL", "summary": "The article focuses on the enterprise value to EBITDA forward for Replimune Group, Inc. (NASDAQ: REPL). It appears to be a financial data snippet or a specific page from a financial tracking platform like TradingView, providing a value for this financial metric. The content itsel", "url": "https://www.tradingview.com/symbols/NASDAQ-REPL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:20", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Replimune\u2019s melanoma drug review, decision due Aug. 2", "summary": "Replimune announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for RP1 combined with nivolumab for advanced melanoma. The FDA classified it as a complete, class 1 response, setting an action date of August 2, 2026, and plans an adviso", "url": "https://www.stocktitan.net/news/REPL/replimune-announces-fda-acceptance-of-rp1-biologics-license-fshs8dnkhxxh.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:09:21", "published_display": "26 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune: FDA Accepts RP1 BLA Resubmission with Aug. 2, 2026 Goal Date", "summary": "The FDA has accepted Replimune's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) with nivolumab for advanced melanoma. The resubmission is categorized as a complete, class 1 response, and the FDA has set a target action date of August 2, 2026,", "url": "https://www.tradingview.com/news/tradingview:604daa00d7987:0-replimune-fda-accepts-rp1-bla-resubmission-with-aug-2-2026-goal-date/", "source_name": "TradingView", "published_at": "2026-06-26T12:09:21", "published_display": "26 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune lead drug accepted for FDA review (REPL:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPRUhmUDJxQkgxWkg4U1dNbnpReV94Z085LWh0bU9ocm5vN29PSGxSWDFNdXpaVjBnRm1lTDJzMG9UVWEtUkM3Q0JkbHZzYTNxMm4wcmRXZU9mSldXeGtTSlMwa0ZJOHpnNWV2RUpmUWtmY3FvMDM2eTdLR1pUNjNZUm1wMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune (REPL) Shares Decline After FDA Advisory Committee Ann", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxPV0R0U3FjNGZMbE92NHFVb1g3TUlrSmphTjh2RHdrT19HZFMwMGp0TmpPMXNQaXZITHQ5V0p3dXRtN2l3N21Ebkl2MkRSOE5UYzlLMWZkdWhoTnFRb1lGT2NzTHhYOE9GSjhVLWtiNm8yaWFsSlRLaHM5QVF4eWZxTi1EcXFhQXpxZlBiUmhTeWpXVU45UmtjVG5zTFNBbmNDUV9xbnNnTWFlTFAyQVZ1QWJ2eGVaZWdlYWlPWGRxZ1NCWnZvLWdTQ2Iwb0FaQUNXX0lqUC15T2dIcDIyUmdtUGJ2cDZndU9GN1RwaXRncTlkOFBtSGRCMjE0ZkRoR2JtVVJlYmlaWFJ3cExtd3pjak9iUG0zV1FmdWd3MXA0eHN4YmN6STZ6S3E4V25uTm8?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Stock Short Interest Falls to 54.56%", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQTUVHTng3d0p0YVkwQ2dvUnExc28zNEpZSWpXLXlZSXRFbUZ4aHNUUXlEbzJYRjRRS2JYaGtabGJjdVlaaTdEczAzUWotOUJmeGhkTHRKYnJValN5X2ljN09oN1dod3VBd2RUdW1TdEtOMXc4ZVBUZW9LSGFvbWxoWWl5VEVWUkxRSHpiTjVtemI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Replimune Group, Inc. \u2013 SWB:7R8", "summary": "This page from TradingView provides financial information for Replimune Group, Inc. (SWB:7R8), specifically focusing on its price-to-earnings forward metric. The content appears to be a stub or a placeholder, as the actual financial data for the chosen period is missing or not di", "url": "https://www.tradingview.com/symbols/SWB-7R8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:57", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Replimune Group, Inc. \u2013 SWB:7R8", "summary": "This article provides financial information for Replimune Group, Inc. (SWB:7R8) on TradingView, specifically focusing on its price-to-sales forward metric. It highlights the company's stock exchange listing and various financial data points available to users. The content primari", "url": "https://www.tradingview.com/symbols/SWB-7R8/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T00:10:46", "published_display": "25 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan upgrades Replimune stock rating on FDA resubmission path", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMDN6OEZEU3FQWWZfNDZybGNBRkVrQWlUSzlILVpEY1JSeXhJMUNndDU2Rkg2SFE2RlJneXJ6ZGszNXJGUnpJQ3luV2hPSWpGdk5sdFhjQVFXRVlWN2ptSzhYY01lMk9TcEl1NnAxOTRGOW9oQnZYd29zb0g5TnJnNkc2WXJ3aDI3OGxfYnVKVURhVVNuaHU2ejlwbWtYalo3MlNmcXE4TXE3LVpUZ3VWMHpqbldCUnBuSy1LT2hSdmhUQ28?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (REPL) Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission Path - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPeG9udHluVG1CWXFHRUMteUYtbVZMMXI3bU10ZlFkaE5nT0ktNHBzRk5MY2R4cXFyLTMzdVVMb0t6WnJQdUl1WXJJVjBWNE9MWkVjN1JyaVZua1VOQjZCOHdsMDhtUXl6NHZ5bWExZ3VPeDNQeTFkeDdJNEFkNlVONnVQdXJaWVh3bUFyc2hkNFJlRzF0TUxDVGZPcWltS3B3OWJ5eDh3Rk1yNEFUR2tYUnNvYy0zMG00TlpHUDNManZKSERMaXRhaE94RWYyZ0xiRkpDYTlyX1RUUHVPNDhkek5oVdIB6AFBVV95cUxQMnhXaEJRSjRmSVZnc0dYemY2SEtnVnVpTU1jSDBHdUFrQm1Zb3A2YmJvZlk2SkE1ZFptb3YwQnJoUy1HRFRxaV9lT24xMUZxNnp2VHU5anV0eF9hUWttN1J0dHg2VkdTWTR5cUVwV1BPVGtiSF8zV3BQUm0wbXlTcmM4SFEyWkIzTl9IWlM4S1d6S2FhSllxdWVDbjEtZmxsV2VlWm9SeTc5WUJ6Qm9uT1FncjIyM3c1TU5PTEo4dlROS3lUQVpCRThpbjJFYWtyUXQtZnlzcnRZeVA0NmtUMzR2UkU3Z004?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock (US76029N1063): ASCO 2026 RP2 data in focus after sharp Nasdaq move", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOTmUxSndQOFBvbHJteFpyeEdTNUgwbXpMVE5JSVM1YzY0SnBua2M4OFVicFZaSG5BbXdSelZGNFVYZmUxa2NtNGlnWGMzZHhoN085ZDZibUg2dTFmc25JeW54bWhNWjZXTVZXeFJHWjhnRTlGbmxxWDVCV2lYS2h2eGx4YTFRbG9PbWdJMkEtelJhM3pQY0VybkpzemNvd3ZoMW1RRkJyMkFxbVZadHZSWkdidnhkZk5TQVpUZEx4Q0VnZjU0WGc?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune reaches agreement with FDA on melanoma drug resubmission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUjBzVUdDQTJuWWpBRkE3NkdDLUhWcVZyMzZBS0FQdW1vU3NGS3lZT2pZTE42ZzU5UjZRWXVCLXRubUJTc2JwQjdQX3JwZVRtZUljTG9KeUNndDNydjc2ZEFSVERfa0tMQk56NFJsQlFxNUVDTGxDSVBfSjVEM0h4Q1pzcmFUTk9pa3d1ZFY0OFU4MFZKekFhYWtxaTB0OWdnTHdCd0hXdEctY1IzZmozSlNnZmRqcUpfb0I1OGR2Zks?oc=5", "source_name": "Investing.com", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA to prioritize Replimune (NASDAQ: REPL) RP1 advanced melanoma BLA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOdnJ4aVNDY3d3M1NnbzBHVUpmSkUwMFZEc2NMSnZUaXFoblV1eXExVDlzQzYxaGlkMlo0UWowNG1HWFNYcFN0Rm1QOXhMdV9mdVFZWkI4NkN1b0s3S2JwYkxyX2p1dXc2Qzd2a0xzcHp6VkZ3d0lCdFNRc0E5NWRBeVU0N1ZOekwxbnk0eGRFaXdiSEMwZUdTREtIbHdJYUJjQTI2NENyeklGVnRa?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock (US76029N1063): focus shifts to RP1 program and cash runway after latest updat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOYlh1eXBCcm1PTnRYQkdUbWdla1gtOHRWaklSX0dYVkhIN2lsMlcxV1BXOWpEOW8wWGxrS0tnTXZHeHE2Y1haeWZ5cGhOWXRXN1lEbHJvOWRJZkVrV0hUZXdGMExOUFlMUHExNkpWeFN1eGk5eW8wNnBVMTlRM0VtR1JlTTV6dnZadU14NlBZSzc5ZW92LWZnMk9LOHdTUUVENnFhdzIxWFNCRmFGcmE0aHdhMllwQ1J4ZWwwMTNveURWbmtnVnF0X053?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Suvretta (REPL) reports 4,221,836 shared holdings in Replimune (5.1%)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOTHBXWjljaGthRkpfQWFqSVBKUS10WjN6dS1LVURPNTkteFlHc1ByazRyd1JFdHNwVXd6S2FRaDZRZC1xUUxEWG9vTWVrdm9qVjNTbHRJbTdCNmM5T0NfaWtYcHJkbWVCTkh4Sy1HOVBkcE05cndBekxaSTliaTVqS3FwOEtaLW94QU9td21kQTA5Z2wxckliTnFRc1lvSU9HX0hvaXNBNXpUOGlKZDJtS2Vwb3lwSWhJUXZhd2k0N082ekxJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock (US76029N1063): FDA rejection of RP1 melanoma therapy draws backlash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSVA5enpla3JCS09MZVBacnpDN1JSMHZ4Y3JtRmFZaXRxdUNmdldVM0FDVWZleFp3VHc3c1N4UTlQZmsxTm5NcEhIRFdRMUhSVDRmcG1TblhFV0Zpa25WZEdicHRvQXJCQ1RCUWFtOEs3MFROQXVyMkxxRFdSTGtKd0QwSVVxcTNQYUxhQ0pXaUx1b3hOa3BPRWh2Z1Y3MWFoYXFXcVVPa3hjTVk1X0xyUU5XMVVjYmdWYnNlX3V5aW0?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: \u2018I Don\u2019t Work For Replimune\u2026\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOTm1lbkRxVXBNbjFVMWtCaWN6X0gzTTh0aW9nMTZ0eGJabUc4T2xQbDMxdTgtVUxZTm95SDJ0R2lGNHJoUnVBSlRRc0szVWdHdnZtRTluVzgwR0VwRlZWSnhZTGxLOXVYWVMtU3JSR3lxWUV1MmhuVGctbFpsS3R6NHRwREhNN3E0bkRGX20wa21DRGtzWnJEaklPa0NtcXdNckRJdDZiN256MXJ1TU9hZzl4REtJZ1FaZXU1cG9vV0d6d05oY2NEODllaDhST0F4el9FeEJwdm1nVGc?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Stock Short Interest Rises to 43.93%", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQbU1kRHFzWENrcWJkdlhjVHJrX3F5QUVETHdiX3RNU1VkN2lLczIzWTdaZmw5OHhDOFVfNUNZNWxOc2JWQlkzV3ZoUS1ya1habmFPQ0laZHBBb0lPQmR0OVo5N0U4TWt4dzB5MmRMcUJlcDhEd2ZKTm54YmFXZmwtZlNBSmR1R0Nfa2FTQ1JyTTM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPNExiSnNYSXpJb0YxQVo4NmNYTzlubElZUW53SFZ6bkN3WkpTSGdiZGc3enZsNGZVT1ZzdUNqYVk2ZlFiSzh2S1BTaWJZTkxja2Vjb3k2S0RBNVB1d01mN3NzcUo2aXEtaHJfcjdXNkhBck12QmI4aU9obFpBVTJvYzE4LWNUd0szMEdES05NMHlpM3phaWxmc1pJczkwczVhTXoxWXdUai00Nkl5ZmQ3NktzaV9GVW1FdXFaZ29YVTNMOUk?oc=5", "source_name": "Reuters", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNeTJIbjItWmZxS19vR3pEZjFUWkhndUpOeGdaQ3FxTlZYR1RWUFk3dzZEM3FOOXAxc0J3OURIYTZrS2xpNzhOY242TlNqMHJuQ19SS25SWHhVQ3JhdlVpNnBqejNfZy0tNll1d3R6aGdmN25qdm4wYl94c3Q0ZmtuR05jOUNaMlMwRmVzTWdsTXNWcVl4YVIzTDBEQ3BieUNicTJpRHg0S1g2LWFXVmI4MFN3?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcWR4QlBvUjZXSUtvcWV3WWx1dy00R0hvd19RR05BYXJLTW5vVEVuWlR5SzB4WjNUODh6Y1FaT2llNnRadHE0dmVCeFNzYmpTVzJVVXNJdTl6OHRPVE81RWZYcWNQMTBLeDBRSmtndWJ2TDd3OUlMbENTM0hBZVBXczhTM0lUZG5nalI1NWZHdW5vVmU3MmFreUVtQTVJQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTlRBTDRVQkpCRjZPLXNiX0ZUMUdnMm5wZThGdW5VbmNrWllCMHl2eGtSVnNqQ3NidThranU0Q2tHTE5tS3RDc1Etb0k2bUVNTjJrLVFCMUVXQUZGdVAtbG5fOVZubjFFSFlDMHEyU2VybUZ6WU45d2Zrb2Zic3BUbklQMG9mTjNwNXNzUUNaMWxzeHZTcW50WEhRUEdRTm8?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA setback for Replimune melanoma drug forces job cuts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTkhUU1FpekQtWHA1MUQ1RUlRUllJUXAzakNTQXZ3WFdFVTdLcDNfQURGYVY5ckFBelpNVE9TdGk5dG5sNnlqQnlmMGt2MzhweGNNMUNKNFZxVVptaUlDdUFSR1daZFRRV2lmeGcyVm01UXJaMjhQVXRUVmZsSkdqdG1nZXhKTFp1Q1lzZUN4RXlGV2lEWWlFVUdfdk9HRVhFNjZpcjRPTmtUYTF1ajlucjZmZVJmWnAyNVBn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Replimune stock gains after updated RP1 data and cash runway outlook", "summary": "Replimune Group Inc. (REPL) stock is reacting to updated clinical data for its oncolytic immunotherapy RP1 and a strengthened cash position. The company reported $357 million in cash and short-term investments as of March 31, 2024, which management expects will fund operations in", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/replimune-stock-gains-after-updated-rp1-data-and-cash-runway-outlook/69827956", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T20:40:09", "published_display": "21 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Replimune Group, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Replimune Group, Inc. (A2JQN1) stocks, offering investors diversified exposure to the company. The ETFs are sorted by their market value of Replimune holdings and include details such as issuer, management style, e", "url": "https://www.tradingview.com/symbols/LS-A2JQN1/etfs/", "source_name": "TradingView", "published_at": "2026-07-20T16:10:26", "published_display": "20 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (REPL) Price Events", "summary": "This article analyzes Replimune Group Inc. (NASDAQ: REPL) stock, identifying weak near- and mid-term sentiment with a neutral long-term outlook. It highlights an exceptional risk-reward short setup and provides three AI-generated trading strategies tailored for different risk pro", "url": "https://news.stocktradersdaily.com/news_release/78/Liquidity_Mapping_Around_REPL_Price_Events_071526054201_1784151721.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T17:42:00", "published_display": "15 Jul 2026 17:42", "sentiment": "negative", "sentiment_pct": 27, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)", "summary": "Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Replimune Group, Inc. (REPL) on behalf of long-term shareholders who held shares continuously since prior to November 22, 2024. The investigation stems from allegatio", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327933/0/en/johnson-fistel-pllp-investigates-claims-on-behalf-of-long-term-shareholders-of-replimune-group-inc-repl.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T15:11:07", "published_display": "15 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Replimune Group, Inc. \u2013 MUN:7R8", "summary": "This article provides the \"Price to earnings forward\" value for Replimune Group, Inc. (MUN:7R8). It indicates that the market is currently closed with no trades. The information is presented on a TradingView page, which also lists various data sources and company information.", "url": "https://www.tradingview.com/symbols/MUN-7R8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T10:12:09", "published_display": "14 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (NASDAQ: REPL) seeks approval to double authorized stock", "summary": "Replimune Group (NASDAQ: REPL) is seeking stockholder approval to amend its charter to double the authorized common stock from 150,000,000 to 300,000,000 shares. This proposal, requiring 75% approval, is part of three proposals to be voted on at the virtual 2026 annual meeting on", "url": "https://www.stocktitan.net/sec-filings/REPL/pre-14a-replimune-group-inc-preliminary-proxy-statement-16079e2475c5.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:42:46", "published_display": "13 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form PRE 14A REPLIMUNE GROUP For: 13 July By Investing.com", "summary": "Investing.com has published a Form PRE 14A for Replimune Group dated July 13. The article provides the filing details, indicates it's from Reuters, and includes the current stock performance for REPL. It also shows a snapshot of various market indices and commodities.", "url": "https://ca.investing.com/news/stock-market-news/form-pre-14a-replimune-group-for-13-july-93CH-4731984", "source_name": "Investing.com Canada", "published_at": "2026-07-13T21:31:10", "published_display": "13 Jul 2026 21:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (REPL) Q4 2026 earnings summary", "summary": "Replimune Group (REPL) reported its Q4 2026 earnings, highlighting the FDA's acceptance of the BLA resubmission for RP1 in advanced melanoma, with a goal date of August 2, 2026. The company experienced a net loss of $313.9 million for the year while its cash reserves decreased to", "url": "https://quartr.com/events/replimune-group-inc-repl-q4-2026_FeJwsKTa", "source_name": "Quartr", "published_at": "2026-07-13T20:42:46", "published_display": "13 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This NASDAQ page provides live quotes and charts for Replimune Group Inc. (REPL), showing its current stock price and basic performance data. It also includes sections for analyst ratings and earnings information, although specific data for these categories are marked as \"N/A\" or", "url": "https://timothysykes.com/quote/REPL/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:10:52", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock and its cancer immunotherapy pipeline", "summary": "Replimune Group Inc. (REPL) is a Nasdaq-listed biotech company specializing in oncolytic immunotherapies for cancer. Their strategy involves engineering viruses to selectively infect and kill cancer cells, while also stimulating an immune response to \"turn cold tumors hot.\" The c", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/replimune-group-stock-and-its-cancer-immunotherapy-pipeline/69724494", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T14:10:56", "published_display": "08 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune says FDA rejected its lead drug for skin cancer", "summary": "Replimune announced that the FDA has rejected its lead drug for skin cancer. The rejection impacts the company's primary therapeutic candidate and its development pipeline.", "url": "https://www.msn.com/en-us/news/other/replimune-says-fda-rejected-its-lead-drug-for-skin-cancer/ar-AA1J3LZ7?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-03T19:09:39", "published_display": "03 Jul 2026 19:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REPL Stock Lost 19% Of Its Value Today \u2013 Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?", "summary": "Replimune Group Inc. (REPL) saw its stock drop 19% after the FDA refused approval for its experimental melanoma drug, RP1. The FDA deemed the submitted data \"insufficient to conclude substantial evidence of effectiveness\" and had previously rejected the initial application in Jul", "url": "https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto", "source_name": "Stocktwits", "published_at": "2026-07-01T05:10:11", "published_display": "01 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bmo-capital-upgrades-replimune-outperform-103226217.html", "source_name": "MT Newswires", "published_at": "2026-06-30T10:32:26+00:00", "published_display": "30 Jun 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update", "summary": "Replimune has released its financial results for the fiscal fourth quarter and year ended March 31, 2026. The report includes key financial figures and a corporate update, offering insights into the company's performance and strategic initiatives for the past year and future outl", "url": "https://www.moomoo.com/hans/news/post/72189851/press-release-replimune-reports-fiscal-fourth-quarter-and-year-end?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T05:10:11", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune's Fiscal Q4 Net Loss Narrows", "summary": "Replimune (NASDAQ: REPL) reported a narrower net loss for its fiscal fourth quarter, coming in at $0.78 per share compared to $0.85 per share in the prior year. The company's total revenue for the quarter was $7.3 million, primarily driven by product sales. Replimune is an oncolo", "url": "https://www.moomoo.com/news/post/72191313/replimune-s-fiscal-q4-net-loss-narrows", "source_name": "Moomoo", "published_at": "2026-06-29T18:41:11", "published_display": "29 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-lifts-price-target-replimune-155544822.html", "source_name": "MT Newswires", "published_at": "2026-06-29T15:55:44+00:00", "published_display": "29 Jun 2026 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Inc reports results for the quarter ended March 31 - Earnings Summary", "summary": "Replimune Group Inc has released its earnings summary for the quarter ended March 31. The report contains financial results for the specified period. Further details are available through the provided source, Refinitiv.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N4310ZH:0-replimune-group-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-06-29T12:39:57", "published_display": "29 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA", "summary": "Replimune Group, Inc. (REPL) reported a widened net loss of $313.9 million for fiscal year 2026, compared to $247.3 million in the previous year, with operating expenses reaching $319.9 million. Despite the increased losses and a reduced cash position of $268.9 million (expected ", "url": "https://www.stocktitan.net/sec-filings/REPL/8-k-replimune-group-inc-reports-material-event-9445d6900162.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:39:57", "published_display": "29 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M \u2014 10-K Summary", "summary": "Replimune Group, Inc. reported a net loss of $(313.94)M for fiscal year 2026, an increase from the $(247.30)M net loss in fiscal 2025, with no reported product revenue. The company is actively investing in research and development for its lead programs RP1, RP2, and RP3, advancin", "url": "https://www.tradingview.com/news/tradingview:252b2617eacb4:0-replimune-group-fy-2026-revenue-0-net-loss-313-9-m-10-k-summary/", "source_name": "TradingView", "published_at": "2026-06-29T12:39:57", "published_display": "29 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune upgraded by Analyst with a new price target", "summary": "Replimune (REPL) has received a new analyst upgrade, which was promptly alerted to Quantisnow Plus members. The company's stock is being watched by Beagle, a market research tool that provides real-time alerts on news, SEC filings, and other market-moving events. Quantisnow is a ", "url": "https://www.quantisnow.com/insight/replimune-upgraded-by-analyst-with-a-new-price-target-6617005", "source_name": "Quantisnow", "published_at": "2026-06-29T12:10:44", "published_display": "29 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune\u2019s melanoma drug review moves toward Aug. 2 FDA decision", "summary": "Replimune reported its fiscal Q4 and full-year 2026 financial results, with a net loss of $313.9 million, and provided a corporate update. The FDA accepted the BLA resubmission for RP1 + nivolumab in advanced melanoma, setting an August 2, 2026 goal date and an advisory committee", "url": "https://www.stocktitan.net/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-uf2j34aykgsk.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:39:57", "published_display": "29 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update", "summary": "Replimune Group, Inc. has announced its financial results for the fiscal fourth quarter and year ended March 31, 2026, alongside a significant corporate update. The FDA has accepted the resubmission of their Biologics License Application (BLA) for RP1 in combination with nivoluma", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/replimune-reports-fiscal-fourth-quarter-and-year-end-2026-financial-results-and-provides-corporate-update/2374827", "source_name": "The Manila Times", "published_at": "2026-06-29T11:39:57", "published_display": "29 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class Action - Contact Levi & Korsinsky", "summary": "Levi & Korsinsky LLP has issued an investor alert for Replimune Group, Inc. (REPL) shareholders, reminding them about the approaching deadline to join a class action lawsuit. The lawsuit alleges that Replimune made false statements regarding its IGNYTE trial, which resulted in th", "url": "https://natlawreview.com/press-releases/investor-alert-deadline-approaching-join-replimune-group-inc-repl-class", "source_name": "The National Law Review", "published_at": "2026-06-28T15:10:46", "published_display": "28 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma", "summary": "Replimune Group, Inc. announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma. The FDA considers this a complete, class 1 response, with a decision expected by August 2, 2026, and ", "url": "https://www.manilatimes.net/2026/06/26/tmt-newswire/globenewswire/replimune-announces-fda-acceptance-of-rp1-biologics-license-application-resubmission-for-advanced-melanoma/2373657/amp", "source_name": "The Manila Times", "published_at": "2026-06-26T20:06:00", "published_display": "26 Jun 2026 20:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-upgrades-replimune-group-overweight-155618861.html", "source_name": "MT Newswires", "published_at": "2026-06-26T15:56:18+00:00", "published_display": "26 Jun 2026 15:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.", "summary": "Replimune Group Inc. has announced that the U.S. FDA has accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1, intended for advanced melanoma treatment. This marks a significant step in the marketing process for their oncolytic virus im", "url": "https://www.bitget.com/amp/news/detail/12560605479113", "source_name": "Bitget", "published_at": "2026-06-26T15:10:24", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Says FDA Accepts Melanoma Drug Resubmission, Sets Aug. 2 Target Action Date", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/replimune-says-fda-accepts-melanoma-123655329.html", "source_name": "MT Newswires", "published_at": "2026-06-26T12:36:55+00:00", "published_display": "26 Jun 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Replimune\u2019s resubmitted application for RP1", "summary": "The FDA has accepted Replimune Group, Inc.'s resubmitted Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, classifying it as a complete, class 1 response with a goal date of August 2, 2026. An advisory committee meeting is scheduled for la", "url": "https://www.investing.com/news/company-news/fda-accepts-replimunes-resubmitted-application-for-rp1-93CH-4762677", "source_name": "Investing.com", "published_at": "2026-06-26T13:09:20", "published_display": "26 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Replimune Group, Inc. \u2013 NASDAQ:REPL", "summary": "The article focuses on the enterprise value to EBITDA forward for Replimune Group, Inc. (NASDAQ: REPL). It appears to be a financial data snippet or a specific page from a financial tracking platform like TradingView, providing a value for this financial metric. The content itsel", "url": "https://www.tradingview.com/symbols/NASDAQ-REPL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:20", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Replimune\u2019s melanoma drug review, decision due Aug. 2", "summary": "Replimune announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for RP1 combined with nivolumab for advanced melanoma. The FDA classified it as a complete, class 1 response, setting an action date of August 2, 2026, and plans an adviso", "url": "https://www.stocktitan.net/news/REPL/replimune-announces-fda-acceptance-of-rp1-biologics-license-fshs8dnkhxxh.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:09:21", "published_display": "26 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune: FDA Accepts RP1 BLA Resubmission with Aug. 2, 2026 Goal Date", "summary": "The FDA has accepted Replimune's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) with nivolumab for advanced melanoma. The resubmission is categorized as a complete, class 1 response, and the FDA has set a target action date of August 2, 2026,", "url": "https://www.tradingview.com/news/tradingview:604daa00d7987:0-replimune-fda-accepts-rp1-bla-resubmission-with-aug-2-2026-goal-date/", "source_name": "TradingView", "published_at": "2026-06-26T12:09:21", "published_display": "26 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune lead drug accepted for FDA review (REPL:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPRUhmUDJxQkgxWkg4U1dNbnpReV94Z085LWh0bU9ocm5vN29PSGxSWDFNdXpaVjBnRm1lTDJzMG9UVWEtUkM3Q0JkbHZzYTNxMm4wcmRXZU9mSldXeGtTSlMwa0ZJOHpnNWV2RUpmUWtmY3FvMDM2eTdLR1pUNjNZUm1wMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune (REPL) Shares Decline After FDA Advisory Committee Ann", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxPV0R0U3FjNGZMbE92NHFVb1g3TUlrSmphTjh2RHdrT19HZFMwMGp0TmpPMXNQaXZITHQ5V0p3dXRtN2l3N21Ebkl2MkRSOE5UYzlLMWZkdWhoTnFRb1lGT2NzTHhYOE9GSjhVLWtiNm8yaWFsSlRLaHM5QVF4eWZxTi1EcXFhQXpxZlBiUmhTeWpXVU45UmtjVG5zTFNBbmNDUV9xbnNnTWFlTFAyQVZ1QWJ2eGVaZWdlYWlPWGRxZ1NCWnZvLWdTQ2Iwb0FaQUNXX0lqUC15T2dIcDIyUmdtUGJ2cDZndU9GN1RwaXRncTlkOFBtSGRCMjE0ZkRoR2JtVVJlYmlaWFJ3cExtd3pjak9iUG0zV1FmdWd3MXA0eHN4YmN6STZ6S3E4V25uTm8?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Stock Short Interest Falls to 54.56%", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQTUVHTng3d0p0YVkwQ2dvUnExc28zNEpZSWpXLXlZSXRFbUZ4aHNUUXlEbzJYRjRRS2JYaGtabGJjdVlaaTdEczAzUWotOUJmeGhkTHRKYnJValN5X2ljN09oN1dod3VBd2RUdW1TdEtOMXc4ZVBUZW9LSGFvbWxoWWl5VEVWUkxRSHpiTjVtemI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Replimune Group, Inc. \u2013 SWB:7R8", "summary": "This page from TradingView provides financial information for Replimune Group, Inc. (SWB:7R8), specifically focusing on its price-to-earnings forward metric. The content appears to be a stub or a placeholder, as the actual financial data for the chosen period is missing or not di", "url": "https://www.tradingview.com/symbols/SWB-7R8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:57", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Replimune Group, Inc. \u2013 SWB:7R8", "summary": "This article provides financial information for Replimune Group, Inc. (SWB:7R8) on TradingView, specifically focusing on its price-to-sales forward metric. It highlights the company's stock exchange listing and various financial data points available to users. The content primari", "url": "https://www.tradingview.com/symbols/SWB-7R8/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T00:10:46", "published_display": "25 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan upgrades Replimune stock rating on FDA resubmission path", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMDN6OEZEU3FQWWZfNDZybGNBRkVrQWlUSzlILVpEY1JSeXhJMUNndDU2Rkg2SFE2RlJneXJ6ZGszNXJGUnpJQ3luV2hPSWpGdk5sdFhjQVFXRVlWN2ptSzhYY01lMk9TcEl1NnAxOTRGOW9oQnZYd29zb0g5TnJnNkc2WXJ3aDI3OGxfYnVKVURhVVNuaHU2ejlwbWtYalo3MlNmcXE4TXE3LVpUZ3VWMHpqbldCUnBuSy1LT2hSdmhUQ28?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (REPL) Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission Path - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock (US76029N1063): ASCO 2026 RP2 data in focus after sharp Nasdaq move", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOTmUxSndQOFBvbHJteFpyeEdTNUgwbXpMVE5JSVM1YzY0SnBua2M4OFVicFZaSG5BbXdSelZGNFVYZmUxa2NtNGlnWGMzZHhoN085ZDZibUg2dTFmc25JeW54bWhNWjZXTVZXeFJHWjhnRTlGbmxxWDVCV2lYS2h2eGx4YTFRbG9PbWdJMkEtelJhM3pQY0VybkpzemNvd3ZoMW1RRkJyMkFxbVZadHZSWkdidnhkZk5TQVpUZEx4Q0VnZjU0WGc?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune reaches agreement with FDA on melanoma drug resubmission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUjBzVUdDQTJuWWpBRkE3NkdDLUhWcVZyMzZBS0FQdW1vU3NGS3lZT2pZTE42ZzU5UjZRWXVCLXRubUJTc2JwQjdQX3JwZVRtZUljTG9KeUNndDNydjc2ZEFSVERfa0tMQk56NFJsQlFxNUVDTGxDSVBfSjVEM0h4Q1pzcmFUTk9pa3d1ZFY0OFU4MFZKekFhYWtxaTB0OWdnTHdCd0hXdEctY1IzZmozSlNnZmRqcUpfb0I1OGR2Zks?oc=5", "source_name": "Investing.com", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA to prioritize Replimune (NASDAQ: REPL) RP1 advanced melanoma BLA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOdnJ4aVNDY3d3M1NnbzBHVUpmSkUwMFZEc2NMSnZUaXFoblV1eXExVDlzQzYxaGlkMlo0UWowNG1HWFNYcFN0Rm1QOXhMdV9mdVFZWkI4NkN1b0s3S2JwYkxyX2p1dXc2Qzd2a0xzcHp6VkZ3d0lCdFNRc0E5NWRBeVU0N1ZOekwxbnk0eGRFaXdiSEMwZUdTREtIbHdJYUJjQTI2NENyeklGVnRa?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock (US76029N1063): focus shifts to RP1 program and cash runway after latest updat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOYlh1eXBCcm1PTnRYQkdUbWdla1gtOHRWaklSX0dYVkhIN2lsMlcxV1BXOWpEOW8wWGxrS0tnTXZHeHE2Y1haeWZ5cGhOWXRXN1lEbHJvOWRJZkVrV0hUZXdGMExOUFlMUHExNkpWeFN1eGk5eW8wNnBVMTlRM0VtR1JlTTV6dnZadU14NlBZSzc5ZW92LWZnMk9LOHdTUUVENnFhdzIxWFNCRmFGcmE0aHdhMllwQ1J4ZWwwMTNveURWbmtnVnF0X053?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Suvretta (REPL) reports 4,221,836 shared holdings in Replimune (5.1%)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOTHBXWjljaGthRkpfQWFqSVBKUS10WjN6dS1LVURPNTkteFlHc1ByazRyd1JFdHNwVXd6S2FRaDZRZC1xUUxEWG9vTWVrdm9qVjNTbHRJbTdCNmM5T0NfaWtYcHJkbWVCTkh4Sy1HOVBkcE05cndBekxaSTliaTVqS3FwOEtaLW94QU9td21kQTA5Z2wxckliTnFRc1lvSU9HX0hvaXNBNXpUOGlKZDJtS2Vwb3lwSWhJUXZhd2k0N082ekxJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group stock (US76029N1063): FDA rejection of RP1 melanoma therapy draws backlash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSVA5enpla3JCS09MZVBacnpDN1JSMHZ4Y3JtRmFZaXRxdUNmdldVM0FDVWZleFp3VHc3c1N4UTlQZmsxTm5NcEhIRFdRMUhSVDRmcG1TblhFV0Zpa25WZEdicHRvQXJCQ1RCUWFtOEs3MFROQXVyMkxxRFdSTGtKd0QwSVVxcTNQYUxhQ0pXaUx1b3hOa3BPRWh2Z1Y3MWFoYXFXcVVPa3hjTVk1X0xyUU5XMVVjYmdWYnNlX3V5aW0?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: \u2018I Don\u2019t Work For Replimune\u2026\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOTm1lbkRxVXBNbjFVMWtCaWN6X0gzTTh0aW9nMTZ0eGJabUc4T2xQbDMxdTgtVUxZTm95SDJ0R2lGNHJoUnVBSlRRc0szVWdHdnZtRTluVzgwR0VwRlZWSnhZTGxLOXVYWVMtU3JSR3lxWUV1MmhuVGctbFpsS3R6NHRwREhNN3E0bkRGX20wa21DRGtzWnJEaklPa0NtcXdNckRJdDZiN256MXJ1TU9hZzl4REtJZ1FaZXU1cG9vV0d6d05oY2NEODllaDhST0F4el9FeEJwdm1nVGc?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group Stock Short Interest Rises to 43.93%", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQbU1kRHFzWENrcWJkdlhjVHJrX3F5QUVETHdiX3RNU1VkN2lLczIzWTdaZmw5OHhDOFVfNUNZNWxOc2JWQlkzV3ZoUS1ya1habmFPQ0laZHBBb0lPQmR0OVo5N0U4TWt4dzB5MmRMcUJlcDhEd2ZKTm54YmFXZmwtZlNBSmR1R0Nfa2FTQ1JyTTM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPNExiSnNYSXpJb0YxQVo4NmNYTzlubElZUW53SFZ6bkN3WkpTSGdiZGc3enZsNGZVT1ZzdUNqYVk2ZlFiSzh2S1BTaWJZTkxja2Vjb3k2S0RBNVB1d01mN3NzcUo2aXEtaHJfcjdXNkhBck12QmI4aU9obFpBVTJvYzE4LWNUd0szMEdES05NMHlpM3phaWxmc1pJczkwczVhTXoxWXdUai00Nkl5ZmQ3NktzaV9GVW1FdXFaZ29YVTNMOUk?oc=5", "source_name": "Reuters", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNeTJIbjItWmZxS19vR3pEZjFUWkhndUpOeGdaQ3FxTlZYR1RWUFk3dzZEM3FOOXAxc0J3OURIYTZrS2xpNzhOY242TlNqMHJuQ19SS25SWHhVQ3JhdlVpNnBqejNfZy0tNll1d3R6aGdmN25qdm4wYl94c3Q0ZmtuR05jOUNaMlMwRmVzTWdsTXNWcVl4YVIzTDBEQ3BieUNicTJpRHg0S1g2LWFXVmI4MFN3?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcWR4QlBvUjZXSUtvcWV3WWx1dy00R0hvd19RR05BYXJLTW5vVEVuWlR5SzB4WjNUODh6Y1FaT2llNnRadHE0dmVCeFNzYmpTVzJVVXNJdTl6OHRPVE81RWZYcWNQMTBLeDBRSmtndWJ2TDd3OUlMbENTM0hBZVBXczhTM0lUZG5nalI1NWZHdW5vVmU3MmFreUVtQTVJQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTlRBTDRVQkpCRjZPLXNiX0ZUMUdnMm5wZThGdW5VbmNrWllCMHl2eGtSVnNqQ3NidThranU0Q2tHTE5tS3RDc1Etb0k2bUVNTjJrLVFCMUVXQUZGdVAtbG5fOVZubjFFSFlDMHEyU2VybUZ6WU45d2Zrb2Zic3BUbklQMG9mTjNwNXNzUUNaMWxzeHZTcW50WEhRUEdRTm8?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA setback for Replimune melanoma drug forces job cuts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTkhUU1FpekQtWHA1MUQ1RUlRUllJUXAzakNTQXZ3WFdFVTdLcDNfQURGYVY5ckFBelpNVE9TdGk5dG5sNnlqQnlmMGt2MzhweGNNMUNKNFZxVVptaUlDdUFSR1daZFRRV2lmeGcyVm01UXJaMjhQVXRUVmZsSkdqdG1nZXhKTFp1Q1lzZUN4RXlGV2lEWWlFVUdfdk9HRVhFNjZpcjRPTmtUYTF1ajlucjZmZVJmWnAyNVBn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 110, "total_relevant": 64, "sentiment_summary": {"positive": 13, "negative": 11, "neutral": 40, "score": 50, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 10.23, "latest_week": "2026-07-17", "one_week_move": -6.9, "four_week_move": 0.4, "twelve_week_move": 322.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.896867, "market_dynamics_buy_signal": false, "relative_strength": 27.084144, "fair_value_gap": 5.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.1886, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.9% over one week, +0.4% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "Ad-hoc-news.de", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.9% over one week, +0.4% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Replimune stock gains after updated RP1 data and cash runway outlook"}], "updated_at": "2026-07-23T05:09:17.507170+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}